• This article examines whether Baxter International at around US$19.38 is a bargain or a value trap, by breaking down what the current price could be implying about the stock.
• The stock has risen 3.2% over the past week and 14.1% over the past month, yet it is still down 0.6% year to date and has fallen 35.4% over the last 12 months.
• Recent coverage of Baxter International has focused on its role in healthcare equipment and on how investors are reassessing companies in this part of the market. This helps explain the mix of short term strength and longer term weakness, and sets the scene for a closer look at what investors might currently be paying for.
• Simply Wall St's valuation model gives Baxter International a value score of 5/6, and the rest of this article will compare different valuation approaches before rounding out with a framework that can help you understand the stock's value in a more complete way.

Approach 1: Baxter International Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Baxter International is expected to generate in the future and discounts those projections back to what they could be worth in today’s dollars.

For Baxter International, the latest reported free cash flow is about $751.4 million. Simply Wall St uses a 2 Stage Free Cash Flow to Equity model, which blends analyst estimates and longer term extrapolations. For example, projected free cash flow for 2028 is $899 million, and the broader ten year path of forecast and extrapolated cash flows runs from $1,073 million in 2026 to $1,091 million in 2035, all in $ terms.

When those cash flows are discounted back and aggregated, the model arrives at an estimated intrinsic value of about $27.35 per share. With a current share price around $19.38, this corresponds to a 29.1% implied discount, which indicates that the stock is trading below this particular estimate of underlying value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Baxter International is undervalued by 29.1%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Baxter International Price vs Sales

For companies where revenue is a key anchor and earnings can be volatile, the P/S ratio is a useful way to think about what you are paying for each dollar of sales. It is often used alongside cash flow based work like the DCF you have just seen.

In general, higher growth expectations and lower perceived risk can support a higher normal multiple, while slower growth or higher risk typically point to a lower one. For Baxter International, the current P/S ratio is 0.88x, compared with the Medical Equipment industry average of 2.79x and a peer average of 5.09x.

Simply Wall St also calculates a Fair Ratio for Baxter International of 1.15x. This is a proprietary estimate of what Baxter International’s P/S ratio could be given factors such as its earnings growth profile, industry, profit margin, market cap and specific risks. Because it adjusts for these company level features, the Fair Ratio offers a more tailored reference point than a simple comparison with industry or peer averages.

Comparing the Fair Ratio of 1.15x with the current P/S of 0.88x suggests the stock is trading below this tailored benchmark.

Result: UNDERVALUED

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Upgrade Your Decision Making: Choose your Baxter International Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Narratives bring that to life by letting you connect your view of Baxter International’s story with explicit assumptions for future revenue, earnings and margins. These then flow into a Fair Value that you can compare with the current share price to help decide whether the stock appears attractive or stretched.

On Simply Wall St’s Community page, Narratives are an easy tool used by millions of investors. Each Narrative ties a clear thesis to a financial forecast and a Fair Value, updates automatically when new news or earnings are released, and lets you see, for example, how one Baxter International Narrative might lean towards the higher Fair Value of about US$33.29 while another sits closer to the lower Fair Value of about US$18.00. This can help you judge which story best fits your own expectations before making any buy or sell decision.

For Baxter International however we will make it really easy for you with previews of two leading Baxter International Narratives:

Fair Value: US$21.54

Implied discount vs current price: about 10.0% below this Fair Value

Assumed revenue growth: 2.16%

• Analysts in this camp see gradual revenue growth and a shift from losses today to positive earnings by 2029, supported by a recovery in hospital activity and patient admissions.
• They expect margin repair as portfolio changes, cost reductions and focus on higher margin products start to show up in profitability.
• The Fair Value of US$21.54 is built on the idea that Baxter could eventually support a P/E of 23.6x on those 2029 earnings, with investors weighing both the upside and the execution risks around hospital volumes, supply chain and quality issues.

Fair Value: US$18.00

Implied premium vs current price: about 7.7% above this Fair Value

Assumed revenue growth: 1.59%

• The cautious view leans on slower expected revenue growth and only modest margin improvement, with pressure from healthcare cost controls and a shift toward preventive and at home care that could weigh on Baxter's hospital focused products.
• Restructuring, divestitures and operational issues such as product pauses and supply chain challenges are seen as potential drags on scale and profitability.
• Here, the Fair Value of US$18.00 assumes Baxter trades on a 20.9x P/E by 2029, and suggests the current share price already reflects much of this scenario, leaving less room if execution disappoints.

Between these two Narratives, you can see how different assumptions on revenue growth, margins and future P/E multiples lead to different views on whether Baxter International looks attractively priced or already full. The key step now is to decide which story lines up more closely with your own expectations for the business and your tolerance for the risks highlighted in each case.

Do you think there's more to the story for Baxter International? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.